(Total Views: 421)
Posted On: 05/08/2025 2:35:34 AM
Post# of 154603
I’ve seen some debate on other boards…
“Do you think 28 patients is too anecdotal for any approval of Leronlimab, or even for it to be taken seriously?’”
Maybe not. But remember, management has the data from other cancers and the sum total probably makes the molecule’s efficacy (and safety) undeniable.
“Do you think 28 patients is too anecdotal for any approval of Leronlimab, or even for it to be taken seriously?’”
Maybe not. But remember, management has the data from other cancers and the sum total probably makes the molecule’s efficacy (and safety) undeniable.
(11)
(0)
